Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMB102
- Development stage
- Preclinical
- Lead developer
- IM Biologics
- Modality
- Small Molecules
01
Overview
IMB102 is a preclinical small molecule drug candidate being developed by ImCare Biotech for the treatment of hepatocellular carcinoma (HCC) and other cancers. The drug functions as an inhibitor of Serine Protease Inhibitor Kazal (SPIK), a protein that is frequently upregulated in HCC and acts to suppress the pro-apoptotic activity of Granzyme A (GzmA). By blocking SPIK, IMB102 restores the immune system's natural capacity to eliminate malignant cells via the SPIK/GzmA pathway. Discovered through high-throughput screening, IMB102 has demonstrated an IC50 of approximately 1µM in vitro, representing a novel immunotherapy approach aimed at enhancing immune-mediated tumor cell death.
02
Targets
DNA
Beyond the preview
Go deeper on IMB102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMB102.